|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rahib L, Smith BD, Aizenberg R, Rosenzweig
AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and
deaths to 2030: The unexpected burden of thyroid, liver, and
pancreas cancers in the United States. Cancer Res. 74:2913–2921.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nevala-Plagemann C, Hidalgo M and
Garrido-Laguna I: From state-of-the-art treatments to novel
therapies for advanced-stage pancreatic cancer. Nat Rev Clin Oncol.
17:108–123. 2020. View Article : Google Scholar
|
|
4
|
Grice GL and Nathan JA: The recognition of
ubiquitinated proteins by the proteasome. Cell Mol Life Sci.
73:3497–3506. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Maxwell BA, Gwon Y, Mishra A, Peng J,
Nakamura H, Zhang K, Kim HJ and Taylor JP: Ubiquitination is
essential for recovery of cellular activities after heat shock.
Science. 372:eabc35932021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Salas-Lloret D and Gonzalez-Prieto R:
Insights in post-translational modifications: Ubiquitin and SUMO.
Int J Mol Sci. 23:32812022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Swatek KN and Komander D: Ubiquitin
modifications. Cell Res. 26:399–422. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Middleton AJ, Teyra J, Zhu J, Sidhu SS and
Day CL: Identification of ubiquitin variants that inhibit the E2
ubiquitin conjugating enzyme, Ube2k. ACS Chem Biol. 16:1745–1756.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Middleton AJ and Day CL: The molecular
basis of lysine 48 ubiquitin chain synthesis by Ube2K. Sci Rep.
5:167932015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cook BW, Lacoursiere RE and Shaw GS:
Recruitment of ubiquitin within an E2 chain elongation complex.
Biophys J. 118:1679–1689. 2020.
|
|
11
|
Song S, Kim SY, Hong YM, Jo DG, Lee JY,
Shim SM, Chung CW, Seo SJ, Yoo YJ, Koh JY, et al: Essential role of
E2-25K/Hip-2 in mediating amyloid-beta neurotoxicity. Mol Cell.
12:553–563. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
de Pril R, Fischer DF, Roos RA and van
Leeuwen FW: Ubiquitin-conjugating enzyme E2-25K increases aggregate
formation and cell death in polyglutamine diseases. Mol Cell
Neurosci. 34:10–19. 2007. View Article : Google Scholar
|
|
13
|
Su J, Huang P, Qin M, Lu Q, Sang X, Cai Y,
Wang Y, Liu F, Wu R, Wang X, et al: Reduction of HIP2 expression
causes motor function impairment and increased vulnerability to
dopaminergic degeneration in Parkinson's disease models. Cell Death
Dis. 9:10202018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tak YJ and Kang S: The E2
ubiquitin-conjugating enzyme HIP2 is a crucial regulator of quality
control against mutant SOD1 proteotoxicity. Biochim Biophys Acta
Mol Basis Dis. 1868:1663162022. View Article : Google Scholar
|
|
15
|
Wang Q, Dong Z, Su J, Huang J, Xiao P,
Tian L, Chen Y, Ma L and Chen X: Ixazomib inhibits myeloma cell
proliferation by targeting UBE2K. Biochem Biophys Res Commun.
549:1–7. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu J, Tian B, Yang J, Huo H, Song Z, Yu J
and Gu Y: Reduction of Hip2 suppresses gastric cancer cell
proliferation, migration, invasion and tumorigenesis. Transl Cancer
Res. 9:774–785. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Coppin L, Leclerc J, Vincent A, Porchet N
and Pigny P: Messenger RNA life-cycle in cancer cells: Emerging
role of conventional and non-conventional RNA-Binding proteins? Int
J Mol Sci. 19:6502018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mancarella C and Scotlandi K: IGF2BP3 from
physiology to cancer: Novel discoveries, unsolved issues, and
future perspectives. Front Cell Dev Biol. 7:3632020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang N, Shen Y, Li H, Chen Y, Zhang P,
Lou S and Deng J: The m6A reader IGF2BP3 promotes acute myeloid
leukemia progression by enhancing RCC2 stability. Exp Mol Med.
54:194–205. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang C, Kong F, Ma J, Miao J, Su P, Yang
H, Li Q and Ma X: IGF2BP3 enhances the mRNA stability of E2F3 by
interacting with LINC00958 to promote endometrial carcinoma
progression. Cell Death Discov. 8:2792022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wan W, Ao X, Chen Q, Yu Y, Ao L, Xing W,
Guo W, Wu X, Pu C, Hu X, et al: METTL3/IGF2BP3 axis inhibits tumor
immune surveillance by upregulating N (6)-methyladenosine
modification of PD-L1 mRNA in breast cancer. Mol Cancer. 21:602022.
View Article : Google Scholar
|
|
22
|
Han J and Hu X: IGF2BP3stabilized SIX4
promotes the proliferation, migration, invasion and tube formation
of ovarian cancer cells. Mol Med Rep. 26:2322022. View Article : Google Scholar
|
|
23
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45(W1):
W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xie X, Lin J, Fan X, Zhong Y, Chen Y, Liu
K, Ren Y, Chen X, Lai D, Li X, et al: LncRNA CDKN2B-AS1 stabilized
by IGF2BP3 drives the malignancy of renal clear cell carcinoma
through epigenetically activating NUF2 transcription. Cell Death
Dis. 12:2012021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang X, Tian L, Li Y, Wang J, Yan B, Yang
L, Li Q, Zhao R, Liu M, Wang P and Sun Y: RBM15 facilitates
laryngeal squamous cell carcinoma progression by regulating TMBIM6
stability through IGF2BP3 dependent. J Exp Clin Cancer Res.
40:802021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang L, Zhang S, Li H and Xu Y, Wu Q, Shen
J, Li T and Xu Y: Quantification of m6A RNA methylation modulators
pattern was a potential biomarker for prognosis and associated with
tumor immune microenvironment of pancreatic adenocarcinoma. BMC
Cancer. 21:8762021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kamisawa T, Wood LD, Itoi T and Takaori K:
Pancreatic cancer. Lancet. 388:73–85. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hershko A: Ubiquitin: Roles in protein
modification and breakdown. Cell. 34:11–12. 1983. View Article : Google Scholar : PubMed/NCBI
|
